Headache Disorders (Cluster & Migraine)

This report summarises what Blossom’s database shows about psychedelics for headache disorders, and what it does not. The story here is genuinely different from the rest of the field in two ways: it began with patients rather than scientists, and the apparent benefit seems not to need a psychedelic experience at all. Both make it fascinating. A third fact keeps it honest: the small controlled trials run so far, in both cluster headache and migraine, have not beaten placebo on their main outcomes. This is a patient-driven, mechanistically distinctive and still-unproven lead.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a treatment recommendation. No psychedelic is approved for any headache disorder. Proven treatments exist and should come first: for cluster headache that includes high-flow oxygen and injectable triptans for attacks, and preventives such as verapamil and CGRP antibodies. Cluster headache is a medical emergency-grade level of pain and needs proper care, not self-experimentation with unregulated substances. If you live with severe headache, please work with a headache specialist; the discussion below is about research, not a route to treatment.

A word on scope and numbers. Blossom tracks dozens of papers and trials under this topic, and those counts appear on the page. Many concern mechanism, general pain, or migraine prevention broadly, and several psilocybin headache trials were terminated. The core of completed, headache-specific controlled trials is very small, just a couple of tiny studies. Read the counts as breadth of interest, not depth of proof.

The story that started with patients

Cluster headache produces attacks of excruciating, strictly one-sided pain, often around the eye, recurring in bouts that can last weeks. It is rare, affecting roughly 1 in 1000 people, and it is severe enough that the older literature and patients alike have called it the "suicide headache". In the early 2000s, members of the cluster-headache community noticed something their doctors had not: small, often sub-recreational doses of psilocybin mushrooms or LSD could abort an attack or, more remarkably, break a whole cluster cycle and extend remission. They pooled their experiences online, and a 2006-era wave of survey research, later consolidated in systematic reviews of patient-reported treatments, found that psilocybin and LSD were rated among the most effective options, frequently above licensed drugs[1]Curr Pain Headache Rep, self-reported cluster headache treatment survey review (2022).

This is close to unique in medicine: a patient community identifying a candidate treatment, organising the evidence, and pulling academic researchers in behind them. It is why any honest account of this topic has to start by taking the patient reports seriously. They are not proof, surveys never are, but they are a large, consistent, hard-to-explain-away signal that earned the formal trials that followed.

The twist: it may not need the trip

The patient discovery came with a pharmacological surprise that sets this area apart from the rest of psychedelic medicine. In depression, the therapeutic effect tends to track the dose and the intensity of the experience. In cluster headache, patients reported that low doses worked, sometimes doses too small to produce much of a psychedelic effect at all, and that what mattered was the repeated "pulse" of a few doses rather than one big journey. The implication is profound: if the anti-headache action does not depend on the subjective trip, then the psychedelic experience is a side effect here, not the mechanism.

That reframes the whole therapeutic goal. It points toward low-dose, repeated regimens and, ultimately, toward non-hallucinogenic analogs such as 2-bromo-LSD that might keep the headache benefit while dropping the trip. And it fits the emerging biology: imaging work has linked the cluster response to changes in the connectivity of the hypothalamus, the deep-brain structure that acts as the cluster-headache clock[2]Headache, cluster response and hypothalamic connectivity (2024), a mechanism that has nothing to do with mood or psychological insight. Headache may be the clearest case in the field of a psychedelic drug working through a decidedly non-psychedelic pathway.

What the controlled trials actually show

Here is where enthusiasm meets evidence, and the evidence is humbling. The first randomised controlled trial of psilocybin in cluster headache, published in 2022, randomised just 14 patients to a low-dose pulse or placebo and found no significant reduction in attack frequency in the weeks afterward[3]Headache, psilocybin cluster headache RCT (2022). The migraine evidence is no stronger: a 2025 randomised trial comparing single- and repeat-dose psilocybin against an active placebo found no advantage for psilocybin, with the placebo group also improving substantially[4]Headache, psilocybin vs active placebo for migraine RCT (2025). Two controlled trials, two primary outcomes not met.

The trials are not the end of the story, but they have to be the centre of an honest one. They were tiny and genuinely hard to blind, and they were chasing an effect that patients describe as intermittent and cycle-dependent, which is difficult to capture in a few weeks of follow-up. Encouragingly, a blinded extension phase did report reductions in attack frequency[5]J Neurol Sci, psilocybin cluster headache blinded extension (2024), and the hypothalamic-connectivity findings give a mechanism to test. But exploratory and extension results cannot substitute for a primary outcome. As it stands, the controlled evidence does not establish that psilocybin or LSD prevents cluster headache or migraine; it establishes that the question is still open.

Ketamine: a separate, limited lane

It is worth separating ketamine out, because it often gets swept into the same heading. Ketamine is not part of the cluster-busting tradition and does not work by interrupting a cluster cycle. It is used off-label as a general analgesic for acute, refractory or chronic daily headache, and some specialist centres give infusions for intractable migraine or status migrainosus. The evidence is mixed and largely uncontrolled, and several controlled headache trials of ketamine have been negative or terminated. It may help some refractory patients in expert hands, but it is a different mechanism and a different story from the serotonergic, patient-led one that defines this page.

Reading this honestly

So where do headache disorders sit? They are the most unusual entry in the psychedelic story and, on current evidence, one of the least proven. The patient discovery is real and remarkable; the mechanism, acting on headache circuitry at low doses without needing a psychedelic experience, is coherent and genuinely exciting; and the unmet need in chronic cluster headache is severe. Against all that sits the plain fact that the controlled trials so far have not beaten placebo, and reviewers remain cautious for exactly that reason[6]Curr Pain Headache Rep, psychedelics for episodic migraine review (2023). For people living with these brutal headaches, the truthful message is twofold: this is one of the most promising and most respectful patient-led leads in the field, worth watching closely and worth proper trials, and it is not yet a treatment, nor a safe thing to improvise with, while the proven options, oxygen, triptans and modern preventives, remain where care should begin.